Department of Pediatrics, Medical University Innsbruck, Innsbruck, Austria.
Curr Rheumatol Rep. 2013 Mar;15(3):312. doi: 10.1007/s11926-012-0312-0.
Childhood systemic lupus erythematosus (SLE) is known to have a worse prognosis than adult-onset disease, and monitoring and treatment of the disease are still a challenge. Thus, there is an urgent need for highly reliable, non-invasive biomarkers for early detection of relapses, to avoid long-term complications and to optimize the management of children with LN. Recent studies of pediatric patients have yielded novel specific biomarkers for SLE diagnosis which can be used for monitoring disease activity and response to treatment. The most promising biomarkers in juvenile-onset SLE include cell-bound complement activation products, some genomic profiles, and urinary proteins such as neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and alpha-1-acid glycoprotein. None of these might be suitable for use as a single SLE-biomarker. More likely a combination of novel biomarkers with traditionally used data, including autoantibodies and complement, might help to enhance sensitivity and specificity for early diagnosis, disease monitoring, and prediction of relapses.cp.
儿童系统性红斑狼疮（SLE）的预后比成人发病者更差，其疾病监测和治疗仍然是一个挑战。因此，迫切需要高度可靠的、非侵入性的生物标志物来早期发现复发，以避免长期并发症，并优化 LN 患儿的管理。最近对儿科患者的研究产生了 SLE 诊断的新型特异性生物标志物，可用于监测疾病活动和治疗反应。在幼年发病的 SLE 中最有前途的生物标志物包括细胞结合的补体激活产物、一些基因组谱和尿蛋白，如中性粒细胞明胶酶相关脂质运载蛋白、单核细胞趋化蛋白-1 和α-1-酸性糖蛋白。这些生物标志物都不适合作为单一的 SLE 生物标志物。更有可能的是，将新型生物标志物与传统使用的数据（包括自身抗体和补体）相结合，可能有助于提高早期诊断、疾病监测和预测复发的敏感性和特异性。
